From: <noreply@neurologysales.bauschhealth.com>
To: <Wellbutrin XL Email Subscribers>
Date: <current date>
Subject 1: Ongoing Savings & Access support

Subject 2: A quick guide to Savings & Access

Subject 3: Savings & Access for your patients

Links to: https://www.wellbutrinxl.com/

Wellbutrin XL® bupropion HCl 150 mg, 300 mg EXTENDED-RELEASE TABLETS

Links to:
https://pi.bauschhealth.com/globalassets/BHC/PI/WellbutrinXL-PI.pdf

Full Prescribing Information, including **Boxed Warning**

Brand-name WELLBUTRIN XL offers ongoing support through Savings & Access



Dear {{lead.First Name}} {{lead.Last Name}},

Insurance coverage hurdles and associated costs should not prohibit your patients from getting on medications you have prescribed.

Below, you will find details regarding brand-name WELLBUTRIN XL® Savings & Access including a $0 copay offer, prior authorization support, and reimbursement assistance to help your patients start and stay on their treatment.

INDICATION

WELLBUTRIN XL® (bupropion hydrochloride) extended-release tablets are indicated for the treatment of major depressive disorder (MDD), and for the prevention of seasonal major depressive episodes in patients with a diagnosis of seasonal affective disorder (SAD). Periodically reevaluate long-term usefulness for the individual patient.

IMPORTANT SAFETY INFORMATION

WARNING: SUICIDAL THOUGHTS AND BEHAVIORS
SUICIDALITY AND ANTIDEPRESSANT DRUGS:
Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term trials. These trials did not show an increase in the risk of suicidal thoughts and behavior with antidepressant use in subjects aged 65 and older.
In patients of all ages who are started on antidepressant therapy, monitor closely for worsening, and for emergence of suicidal thoughts and behaviors. Advise families and caregivers of the need for close observation and communication with the prescriber.

Please see additional Important Safety Information below.

Brand-name WELLBUTRIN XL benefits:

Saving and access every step of the way

1 Copay savings

Eligible* commercially insured patients may pay as little as $0

Wellbutrin XL bupropion HCl EXTENDED-RELEASE TABLETS
BIN# 019158
PCN# CNRX
GRP# AC68001010
ID#
Eligible* commercially insured patients may
PAY AS LITTLE AS $0
*See eligibility criteria and offer details on back.
This card is not health insurance. It cannot be used with Medicare or Medicaid or where restricted.
See enclosed full Prescribing Information, including Medication Guide and Boxed Warning regarding suicidal thoughts and actions.

2 Easy access through PhilRx

- **Troubleshoot** insurance
- Apply a **copay as little as $0** for eligible* commercially insured patients
- Send **reminders** and schedule **refills**
- **Deliver medications** for free

PHIL

Contact PhilRx
Direct Phone Line for Prescribers:
855-652-7445
Website: **phil.us**

3 Simplified prior authorization and reimbursement

Live reimbursement support
From a dedicated specialist

covermymeds®
Assistance with insurance concerns

https://www.wellbutrinxl.com/siteassets/pdf/wxl.0014.usa.24_prior-authorization-considerations-for-wellbutrin-xl.pdf


NAVIGATING PRESCRIPTION COVERAGE REQUIREMENTS
So your patients may access WELLBUTRIN XL® (bupropion hydrochloride) extended-release tablets
Your WELLBUTRIN XL Field Reimbursement Manager will PROVIDE LIVE SUPPORT AND EDUCATION REGARDING:

Reimbursement Considerations for WELLBUTRIN XL


Sample Letter of Medical Necessity

https://www.wellbutrinxl.com/siteassets/pdf/npr-0103-usa-23-sample-letter-medical-necessity.pdf


Sample Medical Exemption Request

Loads WXL.0034.USA.25


Sample Medical Appeal Letter

Loads WXL.0032.USA.25

*This offer is not valid for patients covered by Medicare, Medicaid, or any other federal or state funded healthcare program or where prohibited by law. Please visit www.wellbutrinXL.com for full eligibility criteria, and terms and conditions.

Access support and resources

Links to: https://www.wellbutrinxl.com/for-prescribers/

IMPORTANT SAFETY INFORMATION (cont.)

Contraindications

WELLBUTRIN XL is contraindicated in:

- patients with a seizure disorder
- patients with a current or prior diagnosis of bulimia or anorexia nervosa, due to a higher incidence of seizures
- patients undergoing abrupt discontinuation of alcohol, benzodiazepines, barbiturates, or antiepileptic drugs

- patients taking other bupropion products, including Zyban
- patients taking a monoamine oxidase inhibitor (MAOI) or within 14 days of discontinuing MAOI treatment due to an increased risk of hypertensive reactions. Starting WELLBUTRIN XL in a patient treated with reversible MAOIs such as linezolid or intravenous methylene blue is contraindicated.
- patients with hypersensitivity to bupropion or other ingredients of WELLBUTRIN XL

Warnings and Precautions

- WELLBUTRIN XL is not approved for smoking cessation treatment; however, bupropion HCl sustained-release is approved for this use. Postmarketing reports of serious or clinically significant neuropsychiatric adverse events with smoking cessation treatment have included changes in mood (including depression and mania), psychosis, hallucinations, paranoia, delusions, homicidal ideation, aggression, hostility, agitation, anxiety, and panic, as well as suicidal ideation, suicide attempt, and completed suicide. Observe patients attempting to quit smoking with WELLBUTRIN XL for the occurrence of such symptoms and instruct them to discontinue WELLBUTRIN XL and contact a healthcare provider if they experience such adverse events.
- Bupropion is associated with a dose-related risk of seizures. The dose should not exceed 300 mg once daily. Increase the dose gradually. Discontinue WELLBUTRIN XL and do not restart treatment if the patient experiences a seizure. Use with extreme caution in patients with a history of seizure or cranial trauma, or in patients treated with other medications that lower the seizure threshold.
- Treatment with WELLBUTRIN XL can result in elevated blood pressure and hypertension. Assess blood pressure before initiating treatment with WELLBUTRIN XL and monitor periodically during treatment.
- Antidepressant treatment can precipitate a manic, mixed, or hypomanic manic episode. Prior to initiating WELLBUTRIN XL, screen patients for a history of bipolar disorder and the presence of risk factors for bipolar disorder (e.g., family history of bipolar disorder, suicide, or depression). WELLBUTRIN XL is not approved for the treatment of bipolar depression.
- Depressed patients treated with bupropion have had a variety of neuropsychiatric signs and symptoms, including delusions, hallucinations, psychosis, concentration disturbance, paranoia, and confusion. Some of these patients had a diagnosis of bipolar disorder. In some cases, these symptoms abated upon dose reduction and/or withdrawal of treatment. Discontinue WELLBUTRIN XL if these reactions occur.
- The pupillary dilation that occurs following use of many antidepressant drugs including WELLBUTRIN XL may trigger an angle-closure attack (Angle-Closure Glaucoma) in a patient with anatomically narrow angles who does not have a patent iridectomy.
- Anaphylactoid/anaphylactic reactions have occurred during clinical trials with bupropion, as well as rare, postmarketing reports of erythema multiforme, Stevens-Johnson syndrome, and anaphylactic shock associated with bupropion.

Adverse Reactions

- The most common adverse reactions that occurred in at least 5% of patients treated with bupropion HCl sustained-release (300 mg and 400 mg per day) and at a rate at least twice the placebo rate were: anorexia, dry mouth, nausea, insomnia, dizziness, pharyngitis, abdominal pain, agitation, anxiety, tremor, palpitation, sweating, tinnitus, myalgia, urinary frequency, and rash.

Drug Interactions

- An increased dose of bupropion may be necessary if co-administered with CYP2B6 inducers based on clinical exposure but should not exceed the maximum recommended dose. Bupropion inhibits CYP2D6 and can increase concentrations of: antidepressants, antipsychotics, beta-blockers, and Type 1C antiarrhythmics. Consider dose reduction when using with bupropion. Dose bupropion with caution when used with drugs that lower seizure threshold. CNS toxicity can occur when bupropion is used concomitantly with dopaminergic drugs.
- WELLBUTRIN XL can cause false-positive urine test results for amphetamines.

Use in Specific Populations

- Pregnancy: Use only if benefit outweighs potential risk to the fetus. Healthcare providers are encouraged to register patients in the Pregnancy Exposure Registry by calling 1-844-405-6185 or visiting https://womensmentalhealth.org/research/pregnancyregistry/.
- In patients with moderate to severe hepatic impairment (Child-Pugh score: 7 to 15), the maximum dose is **150 mg every other day.** In patients with mild hepatic impairment (Child-Pugh score: 5 to 6) or renal impairment (glomerular filtration rate <90 mL/min), consider reducing the dose and/or frequency of dosing.
- Advise patients to read the FDA-approved patient labeling (Medication Guide).

To report SUSPECTED ADVERSE REACTIONS, contact Bausch Health at 1-800-321-4576 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Links to:
https://pi.bauschhealth.com/globalassets/BHC/PI/WellbutrinXL-PI.pdf

Links to:
https://www.fda.gov/safety/medwatch-fda-safety-information-and-adverse-event-reporting-program

Click here for full Prescribing Information, including Boxed Warning regarding suicidal thoughts and behaviors.

Links to: https://www.wellbutrinxl.com/for-prescribers/

Access support and resources

BAUSCH Health

Links to:
https://www.bauschhealth.com

Bausch Health Companies Inc. 400 Somerset Corporate Boulevard | Bridgewater, NJ 08807

This email was sent to you because you opted in/requested to receive marketing messages from Bausch Health Neurology. If you no longer wish to receive emails from Bausch Health Neurology, you can update your email preferences below.

Please do not reply to this email. If you have questions related to our products, contact our Customer Care at: 1-800-321-4576.

WELLBUTRIN XL is a registered trademark of GlaxoSmithKline LLC used under license.
Any other product/brand names and/or logos are trademarks of the respective owners.

© 2025 Bausch Health Companies Inc. or its affiliates. WXL.0045.USA.25

UNSUBSCRIBE OR UPDATE EMAIL PREFERENCES | PRIVACY POLICY | LEGAL NOTICE

https://go.bauschhealth.com/Neurology-Preferences-HCP-Existing.html

Links to: https://www.bauschhealth.com/privacy

Links to: https://www.bauschhealth.com/terms